We collaborate with national & international Doctors & Researchers around the world to help educate & provide research about #MOGAD. 501(c)3 🌺 #ViewsAreOurOwn
How does MOGAD affect daily life for children and families around the world?
The global IMPACT Survey invites young people ages 12–20 with MOGAD and parents/guardians of those ages 0–20 to share their experiences.
Anonymous. 20–30 min.
Take part: https://t.co/3kWB7AeQro
Sponsored by UCB.
Let’s debate!
Do you consider a pt who has pain, but no vision loss as an ON attack?
Would you treat these pts despite no vision loss?
We are torn between different practises treating eye pain without vision loss classifying it as ‘ON’ / others are not
Let’s debate!
Do you consider a pt who has pain, but no vision loss as an ON attack?
Would you treat these pts despite no vision loss?
We are torn between different practises treating eye pain without vision loss classifying it as ‘ON’ / others are not
Researchers comparing longitudinal trajectories of global & regional brain atrophy across MS, MOGAD, & AQP4 + NMOSD found that each exhibit distinct patterns of brain structural evolution. Read the full study with all the findings here: https://t.co/SybucZK8hC
For clinicians:
TIMELY-PLEX: Does early plasma exchange improve recovery after severe optic neuritis or myelitis?
Refer within 14 days of symptom onset. See participating sites to refer patients at https://t.co/ULV9k0Zy4M
The MOG Project serves as an advocacy principal investigator.
NCT07100990: https://t.co/kn5WO6PLBR
#MOGAD
🧠 Bilateral thalamic lesions in a child. Unilateral cortical swelling with seizures. Longitudinally extensive myelitis with conus involvement.
Different imaging patterns. One disease.
(MOGAD)
This week's #SPIN tweetorial explores its expanding MRI spectrum. 🧵👇
@chenmayo with a great presentation at #MSTORONTO2026 on #MOGAD treatments including his pioneering approach of “steroid in the pocket” acutely to get in early & prevent disability while also covering observational & clinical trial data on attack-prevention treatments👇
Excellent talk on pediatric #MS#MOGAD a& #NMOSD from @tweetsatakash covering all the latest in acute & maintenance treatment of these diseases along with emerging clinical trials in the field 👇
Welcome Dr. Haiwen Chen to The MOG Project’s Medical & Scientific Advisory Council!
A pediatric neuroimmunologist at Johns Hopkins, Dr. Chen combines clinical MOGAD research with laboratory studies exploring how brain cells influence neuronal communication.
Meet Dr. Chen: https://t.co/zz5BQByJhJ
#MOGAD
🧠 Satralizumab (Enspryng) reduced relapse risk by 68% vs placebo in the phase 3 METEOROID trial in relapsing MOGAD
📊 At 48 weeks, 87.3% of patients receiving satralizumab remained relapse-free vs 66.5% with placebo
🔬 Findings from #CNS2026: https://t.co/rdOxrD4QFJ
#MOGAD #Neurology
How does MOGAD affect daily life for children and families around the world?
The global IMPACT Survey invites young people ages 12–20 with MOGAD and parents/guardians of those ages 0–20 to share their experiences.
Anonymous. 20–30 min.
Take part: https://t.co/3kWB7AeQro
Sponsored by UCB.
New in @GreenJournal a study of 312 children with #MOGAD links IV immunoglobulin (#IVIG) to a 46% lower relapse risk. Observational, so trials are still needed. Congratulations @tweetsatakash and the whole team! 🩵
https://t.co/qmo4HZNxls
Delighted to share our international review on MRI Characteristics of #MOGAD! ➡️ Key imaging features are highlighted across the brain, optic nerves & spinal cord including lesion dynamics ➡️ Illustrative figures help show its full imaging spectrum👇
https://t.co/TdLM1kg3dS
This retrospective cohort study with a preplanned analysis found that prednisolone ≥10 mg treatment for ≥3 months after the index event was associated with a lower likelihood of relapsing MOGAD: https://t.co/addqrxgfI2
Children can develop the full spectrum of MOGAD-like encephalitis without MOG-IgG. Clinical features and immunotherapy response are similar to MOGAD, but relapses are uncommon: https://t.co/uzDuJdiuiu
Hacohen et al. review and assess the current evidence, make clinical considerations, and propose future directions for treatment de-escalation and discontinuation in MOGAD and AQP4-Ab NMOSD: https://t.co/Z06V8eSUTX
Become an @ISNI_neuro member now to be eligible for travel awards to
join us in beautiful Venice. More update on the program soon. #WeAreNeuroimmunology
Antibody-associated disorders such MOGAD and NMOSD rely on antibody tests for their diagnosis, rendering accessibility to testing paramount to the care and treatment of people with MOGAD and NMOSD.
ISNI is pleased to support a worldwide survey on AQP4- and MOG-IgG testing accessibility and laboratory testing strategies with the aiming of mapping the current access to AQP4-IgG and MOG-IgG testing and to understand issues that limit testing access around the world.
Two surveys are available: one for neurologists who request testing and the other one for head scientists and immunopathologists who provide the testing.
Please consider spending 12 minutes to complete one of the surveys.
Learn more & access the survey here: https://t.co/TiJMzWBQrx
@FabienneBrilot , Paddy Waters, matteo gastaldi, @SaraMariottoMD and @hwiendl
#MOGantibodyTaskForce